Register

Hematologic Malignancies

Pediatric Hematology   

Questions discussed in this category

How would you manage a young patient with HL who develops HF (EF < 30%) after 4 cycles of A+AVD who obtained a PET2 CR?
2 Answers available
For T cell ALL treated in CR (without transplant), how often do you do BM biopsies as part of surveillance, and for how long?
What would you want community oncologists to know when following these patients? Are there any other special issues to follow especially in AYA?
1 Answer available
When patients develop headaches from luspatercept, do they tend to improve over time?
1 Answer available
What is the optimal age at which a patient with sickle cell disease should undergo allogeneic stem cell transplant?
2 Answers available
What are your top takeaways from ASH 2022?
8 Answers available
Do you do prophylactic LP/IT chemotherapy in high risk APML prior to starting consolidation?
1 Answer available
Which patients with acute promyelocytic leukemia do you consider maintenance after completing consolidation?
1 Answer available
How will you use Pola-R-CHP in the frontline treatment of DLBCL?
Given the POLARIX study data presented at ASH 2021, will this replace R-CHOP as the standard of care therapy in your practice? If not, how will y...
2 Answers available
What are contraindications for growth factors in patients with hematologic malignancies?
2 Answers available
In which patients with oncologic or hematologic disorders are you recommending a 3rd dose of mRNA COVID vaccine?
2 Answers available
How do you assess whether an early-stage Hodgkin's patient is unfavorable?
The unfavorable risk factors for stage I-II Classic Hodgkin's Lymphoma differ depending on the cooperative group (GHSG, EORTC, NCCN), which criteria d...
1 Answer available


Papers discussed in this category

Ann Oncol, 2021 Mar 18
Association of Clinical Factors and Recent Anti-Cancer Therapy with COVID-19 Severity among Patients with Cancer: A Report from the COVID-19 and Cancer Consortium.
Blood, 2006-05-01
Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-02-01
Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.
Blood, 2017-03-09
Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab.
The Lancet. Oncology, 2015-10
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
N Engl J Med, 2013 Jul 11
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
Blood, 2012 Jun 19
All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).
Blood, 2019-04-11
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet.
N Engl J Med, 2022 Dec 11
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-11-01
Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma.
Blood, 2018 Apr 5
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.
Blood Adv, 2021 Aug 24
Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia.
JAMA, 2023 Aug 8
Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial.
Blood, 2017 Jan 31
Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines.

Related Topics in Hematologic Malignancies

Copyright © 2024 theMednet
All Rights Reserved.